We aimed to explore the potential of Danshensu as a therapeutic agent for liver fibrosis by targeting the pyroptosis-inflammasome signaling pathway, thereby providing a basis for developing effective and safer NLRP3 inflammasome inhibitors. This evidence concerns the gene NLRP3 and Hepatic fibrosis.